CN113826891A - Composition containing compound vitamin and tabletting preparation method and application thereof - Google Patents

Composition containing compound vitamin and tabletting preparation method and application thereof Download PDF

Info

Publication number
CN113826891A
CN113826891A CN202111024930.7A CN202111024930A CN113826891A CN 113826891 A CN113826891 A CN 113826891A CN 202111024930 A CN202111024930 A CN 202111024930A CN 113826891 A CN113826891 A CN 113826891A
Authority
CN
China
Prior art keywords
parts
composition
vitamin
tabletting
nicotinamide mononucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111024930.7A
Other languages
Chinese (zh)
Inventor
王唯薇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Ruixian High Tech Biotechnology Co ltd
Original Assignee
Shanghai Ruixian High Tech Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Ruixian High Tech Biotechnology Co ltd filed Critical Shanghai Ruixian High Tech Biotechnology Co ltd
Priority to CN202111024930.7A priority Critical patent/CN113826891A/en
Publication of CN113826891A publication Critical patent/CN113826891A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/13—Nucleic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/24—Cellulose or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/20—Agglomerating; Granulating; Tabletting
    • A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

The invention discloses a composition containing compound vitamins, which adopts vitamin b group, vitamin b3 derivative nicotinamide mononucleotide, vitamin c, black sesame raw powder, mulberry raw powder, medlar polypeptide component, sea cucumber polypeptide and heme iron; the hair-growing and hair-growing agent also comprises food additives of microcrystalline cellulose and pvp-k30, and has the effects of improving alopecia, relieving fatigue, refreshing and resisting aging.

Description

Composition containing compound vitamin and tabletting preparation method and application thereof
Technical Field
The invention relates to a composition containing compound vitamins and a preparation method and application thereof, in particular to a composition for improving alopecia, relieving fatigue, refreshing and resisting aging and a tabletting preparation method thereof.
The invention particularly relates to a composition for improving alopecia, relieving fatigue, refreshing and resisting aging and a preparation method thereof. The composition comprises a vitamin B group such as nicotinamide mononucleotide and derivatives thereof, and a compound composition of medicinal and edible food powder such as black sesame, medlar, mulberry and the like.
Background
Due to the fact that the modern society is under high working pressure, a large number of people are in sub-health states, long-time work in night is carried out, sleep is reduced, and the influence of unhealthy life styles such as smoking and drinking is caused, so that symptoms such as fatigue, absence of spirit, alopecia and the like appear on the large number of people.
With the coming of aging society, a series of chronic diseases caused by aging seriously affect the health of the old people, and the aging resistance becomes a social problem more and more.
The vitamin b group is an essential product of human metabolism, participates in various key metabolic reactions of the human body, and is an important substance for human anti-aging. Vitamin b has a co-fusion phenomenon, various types of vitamin b compounds are required to be taken simultaneously to effectively improve various functions of a human body, and important vitamin b2 (riboflavin), vitamin b6 (pyridoxine), vitamin b12 (cyanocobalic acid), vitamin b3 (nicotinic acid) and nicotinamide mononucleotide derivatives thereof are included. Vitamin b group is the anti-aging compound which is the most fire-heat researched at present, and the compound can maintain cell activity, comprehensively resist aging, keep the activity of hair follicle cells, promote ATP (adenosine triphosphate) generation, enable hair follicle cells to be active to generate hair protein and improve alopecia.
The black sesame is an important food in homology of medicine and food, is rich in high-quality protein, fatty acids such as oleic acid, linoleic acid and the like, rich in vitamin e, selenium, iron and the like which are the most basic elements for hair growth, can effectively promote cell division, delay cell aging, nourish liver and kidney, nourish essence and blood, relax bowel, relieve constipation, improve symptoms of liver-kidney yin deficiency such as dizziness and tinnitus, soreness and pain of waist and knees, alopecia, premature graying of hair and the like after long-term use, and is a good health food for nourishing liver and kidney, growing hair and preventing alopecia
The mulberry is an important and common food in homology of medicine and food, has the effects of soothing nerves, promoting sleep, reinforcing qi, benefiting needs, improving immunity, improving liver-kidney yin deficiency, moistening hair, blackening hair, improving eyesight and delaying aging, can synthesize melanin, is rich in a large amount of plant selenium and anthocyanin, can effectively relieve fatigue, promote hair growth and improve early graying of hair.
Wolfberry polypeptide: the lycium barbarum polypeptide is a small molecular fragment consisting of a plurality of amino acids, is rich in 22 amino acids, contains 9 essential amino acids which cannot be synthesized by a human body, is low in molecular weight and easy to absorb, can obviously improve learning and memory, can effectively remove in-vivo free radicals, activate an antioxidant defense system and the like, improves the antioxidant capacity of the body, reduces the damage of the free radicals to the body, plays a role in delaying senescence, simultaneously supplements peptides required by the human body every day, maintains cell activity, provides a cell synthesis raw material, and improves immunity.
With the research of vitamins, more and more people pay attention to the development of vitamin products. For example, the invention discloses a functional solid sports drink (application number CN202110432717.3, publication number CN113040308A) belonging to the technical field of solid drinks, and specifically discloses a functional solid sports drink, which comprises beta-nicotinamide mononucleotide, medium-chain triglyceride, glutamine, branched-chain amino acid, active peptide, vitamin B6, sodium chloride, potassium chloride, malto-oligosaccharide, food additive and food essence, and can effectively reduce the content of lactic acid generated after human body movement through the synergistic effect among the components, and has the effects of scavenging free radicals and resisting oxidation, effectively enhancing the storage and accumulation of protein, accelerating the scavenging of substances causing fatigue, maintaining the normal physiological functions of cells, delaying the occurrence of fatigue and accelerating the recovery of fatigue. A functional solid sports beverage comprises the following raw materials in parts by weight: 2.0-6.0 parts of beta-nicotinamide mononucleotide, 30.0-50.0 parts of glutamine, 40.0-60.0 parts of branched chain amino acid, 60.01-0.03 part of vitamin B, 5.0-9.0 parts of sodium chloride, 1.0-2.0 parts of potassium chloride, 1.0-5.0 parts of food additive and 1.0-5.0 parts of food essence.
The existing commercial products related to the vitamin b group, in particular those related to Nicotinamide Mononucleotide (NMN), which is a derivative thereof, generally have several disadvantages:
(1) most of the capsules are used as final product dosage forms, have large volume and are inconvenient to carry and swallow;
(2) the single component has no other functional components, the single function, and the NMN only takes effect to maintain the cell activity, but can not realize the functions of anti-aging and the like in all aspects.
(3) Has low bioavailability and poor absorption. Some capsules release a large amount of the loaded NMN in the stomach, causing premature destruction by gastric acid, and secondly, the capsule disintegration type releases the loaded NMN, which is not conducive to the absorption and utilization of NMN.
Disclosure of Invention
The present invention aims at providing one kind of composite vitamin-containing composition and its preparation process and use, and aims at overcoming the demerits and demerits of available technology.
The invention aims to provide a compound plant essence tablet, which is characterized in that the original vitamin b group product is changed from capsule to tablet, the tablet is convenient to carry and use, the volume is reduced by about 30%, meanwhile, plant essence raw powder rich in protein amino acid and the like required for growing hair and relieving body fatigue is added, the tablet adopts enteric coating, and through the regulation of a disintegrating agent, the premature release in the stomach is avoided, the slow and effective sustained release in the intestinal tract is realized, the effective absorption of the medicine is promoted, and the health care effects of resisting aging, protecting hair and resisting fatigue are comprehensively promoted.
In order to meet the health care requirements of improving alopecia, relieving fatigue, refreshing and resisting aging, the inventor obtains the compound health food tabletting through deep research and creative work, and the required health care target is effectively realized through complementary combination of vitamin B group and plant essence raw powder, so the invention is provided.
The technical problem to be solved by the invention can be realized by the following technical scheme:
as a first aspect of the present invention, a composition containing multivitamins is characterized in that the formula of the food material comprises, in parts by weight:
vitamin b group, black sesame raw powder, mulberry raw powder and medlar polypeptide; a health food in the form of tablet has effects in relieving alopecia, relieving fatigue, refreshing mind, and resisting aging.
Further, the vitamin b group comprises vitamin b2, b3, b6, b12, and vitamin b3 derivative nicotinamide mononucleotide.
Further, the food raw materials also comprise black sesame raw powder, mulberry raw powder, medlar polypeptide, sea cucumber polypeptide and heme iron.
Further, the food raw material also comprises vitamin c.
Furthermore, the food raw material also comprises food additives of microcrystalline cellulose and pvp-k 30.
Further, the food raw materials are proportioned as follows:
Figure BDA0003242971380000031
Figure BDA0003242971380000041
further, the food raw material proportion is preferably as follows:
Figure BDA0003242971380000042
further, the food raw material proportion is preferably as follows:
Figure BDA0003242971380000043
further, the food raw material proportion is preferably as follows:
Figure BDA0003242971380000044
further, the food product is in the form of a tablet.
Further, the content of nicotinamide mononucleotide in the food material is not less than 50 mg (12% m/m) per tablet.
As a second aspect of the present invention, a use of a composition containing multivitamins, characterized in that: is used for preparing health food for improving alopecia, relieving fatigue, refreshing and resisting aging.
As a third aspect of the present invention, a method for preparing a compressed tablet of a vitamin complex-containing food, comprising the steps of:
(1) preparing materials;
(2) granulating;
(3) tabletting;
(4) coating;
(5) and (5) sterilizing.
Wherein, the step (1) comprises the following steps:
Figure BDA0003242971380000051
wherein, the step (2) is granulation: firstly, the nicotinamide mononucleotide is independently sieved by a 40-mesh or above sieve and then fed, all components except magnesium stearate are fully mixed and sieved by a 40-mesh sieve, and the nicotinamide mononucleotide is uniformly mixed with 100-200 parts by weight of 10-90% ethanol (dissolved with PVP-K30) and sieved by a 20-mesh sieve; after being dried, the obtained particles are finished by adopting a 16 or 18-mesh sieve, so that the good flowability of the particle powder is ensured; after finishing the granules, mixing with magnesium stearate, and tabletting.
Wherein, tabletting in the step (3): the weight of the tablet is 0.55 g/tablet, the environmental temperature is controlled to be 18-25 ℃, and the relative humidity is controlled to be 45-60%.
Wherein, the coating in the step (4): coating uniform and compact film coat, controlling the ambient temperature at 18-25 ℃ and the relative humidity at 45-60%.
Wherein, the step (5) is sterilization: tabletting, forming and sterilizing.
Furthermore, in the preparation scheme of the tablet, the preferable use ratio of the ethanol in the granulating step is 50-100 percent
Further, in the above tabletting preparation scheme, the preferable usage ratio of ethanol in the granulating step is 75% to 100%.
Further, in the above tabletting preparation scheme, the preferable usage ratio of ethanol in the granulating step is 95% -100%.
Further, in the preparation scheme of the tabletting, in the granulating step, the granulating and drying temperature is 40-60 ℃, and the drying time is 1-12 hours.
Further, in the above tabletting preparation scheme, in the granulating step, the granulating and drying temperature is 40 ℃, and the drying time is 1-2 hours.
Furthermore, in the above tablet preparation scheme, in the final sterilization step, cobalt 60 irradiation sterilization is preferably adopted, and the intensity is 15-25kgry, and 15kgry is preferably adopted to ensure that the active ingredients of the medicine are not damaged.
In the raw materials, the nicotinamide mononucleotide is prepared by adopting an enzymatic synthesis method, and the purity of the nicotinamide mononucleotide reaches more than 99%.
The invention has the beneficial effects that:
the invention relates to a food containing compound vitamins, which adopts vitamin b group, vitamin b3 derivative nicotinamide mononucleotide, vitamin c, black sesame raw powder, mulberry raw powder, medlar polypeptide component, sea cucumber polypeptide and heme iron; also comprises food additives of microcrystalline cellulose and pvp-k 30. Has effects in relieving alopecia, relieving fatigue, refreshing, and resisting aging.
Detailed Description
The present invention will be further described with reference to the following examples. It should be understood that the following examples are illustrative only and are not intended to limit the scope of the present invention. It will be understood by those skilled in the art that the following examples are illustrative of the present invention only and should not be taken as limiting the scope of the invention. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products commercially available.
Example 1
The method comprises the following steps: ingredients
1000 parts of medlar polypeptide, 1000 parts of mulberry raw powder, 1000 parts of black sesame raw powder, 500 parts of nicotinamide mononucleotide, 500 parts of vitamin c, 25 parts of vitamin b, 65 parts of vitamin b, 35 parts of vitamin b12 (1%), 1.4 parts of microcrystalline cellulose, 1000 parts of PVP K-3020 and 29 parts of magnesium stearate.
Step two: granulating
The nicotinamide mononucleotide is firstly and independently screened by a screen of 40 meshes or above and then fed (the raw material is easy to agglomerate and is unevenly dispersed), all components except magnesium stearate are fully mixed and screened by a screen of 40 meshes, and the nicotinamide mononucleotide is uniformly mixed with 100-200 parts by weight of 10-90% ethanol (dissolved with PVP-K30) and screened by a screen of 20 meshes. After being dried, the obtained particles are finished by adopting a 16 or 18-mesh sieve, so that the good fluidity of the particle powder is ensured. After finishing the granules, mixing with magnesium stearate, and tabletting.
Step three: tabletting
The weight of the tablet is about 0.55 g/tablet, the environmental temperature is controlled to be 18-25 ℃, and the relative humidity is controlled to be 45-60%.
Step four: coating film
Coating uniform and compact film coat, controlling the ambient temperature at 18-25 ℃ and the relative humidity at 45-60%.
Step five: sterilization
Tabletting, forming and sterilizing.
Example 2
The method comprises the following steps: ingredients
700 parts of medlar polypeptide, 700 parts of mulberry raw powder, 700 parts of black sesame raw powder, 1400 parts of nicotinamide mononucleotide, 500 parts of vitamin c, 25 parts of vitamin b, 65 parts of vitamin b, 35 parts of vitamin b12 (1%), 1000 parts of microcrystalline cellulose, PVP K-3020 parts of PVP and 29 parts of magnesium stearate.
Step two: granulating
The nicotinamide mononucleotide is firstly and independently screened by a screen of 40 meshes or above and then fed (the raw material is easy to agglomerate and is unevenly dispersed), all components except magnesium stearate are fully mixed and screened by a screen of 40 meshes, and the nicotinamide mononucleotide is uniformly mixed with 200 parts by weight of 10-90% ethanol (dissolved with PVP-K30) of 100 meshes and screened by a screen of 20 meshes. After being dried, the obtained particles are finished by adopting a 16 or 18-mesh sieve, so that the good fluidity of the particle powder is ensured. After finishing the granules, mixing with magnesium stearate, and tabletting.
Step three: tabletting
The weight of the tablet is 0.55 g/tablet, the environmental temperature is controlled to be 18-25 ℃, and the relative humidity is controlled to be 45-60%.
Step four: coating film
Coating uniform and compact film coat, controlling the ambient temperature at 18-25 ℃ and the relative humidity at 45-60%.
Step five: sterilization
Tabletting, forming and sterilizing.
Example 3
The method comprises the following steps: ingredients
400 parts of medlar polypeptide, 400 parts of mulberry raw powder, 400 parts of black sesame raw powder, 2300 parts of nicotinamide mononucleotide, 500 parts of vitamin c, 25 parts of vitamin b, 65 parts of vitamin b, 35 parts of vitamin b12 (1%), 1000 parts of microcrystalline cellulose, PVP K-3020 and 29 parts of magnesium stearate.
Step two: granulating
The nicotinamide mononucleotide is firstly and independently screened by a screen of 40 meshes or above and then fed (the raw material is easy to agglomerate and is unevenly dispersed), all components except magnesium stearate are fully mixed and screened by a screen of 40 meshes, and the nicotinamide mononucleotide is uniformly mixed with 200 parts by weight of 10-90% ethanol (dissolved with PVP-K30) of 100 meshes and screened by a screen of 20 meshes. After being dried, the obtained particles are finished by adopting a 16 or 18-mesh sieve, so that the good fluidity of the particle powder is ensured. After finishing the granules, mixing with magnesium stearate, and tabletting.
Step three: tabletting
The weight of the tablet is 0.55 g/tablet, the environmental temperature is controlled to be 18-25 ℃, and the relative humidity is controlled to be 45-60%.
Step four: coating film
Coating uniform and compact film coat, controlling the ambient temperature at 18-25 ℃ and the relative humidity at 45-60%.
Step five: sterilization
Tabletting, forming and sterilizing.
Example 4
The method comprises the following steps: ingredients
1100 parts of wolfberry polypeptide, 1100 parts of mulberry raw powder, 1100 parts of black sesame raw powder, 200 parts of nicotinamide mononucleotide, 500 parts of vitamin c, 25 parts of vitamin b, 65 parts of vitamin b, 35 parts of vitamin b12 (1%), 1000 parts of microcrystalline cellulose, PVP K-3020 and 29 parts of magnesium stearate.
Step two: granulating
The nicotinamide mononucleotide is firstly and independently screened by a screen of 40 meshes or above and then fed (the raw material is easy to agglomerate and is unevenly dispersed), all components except magnesium stearate are fully mixed and screened by a screen of 40 meshes, and the nicotinamide mononucleotide is uniformly mixed with 200 parts by weight of 10-90% ethanol (dissolved with PVP-K30) of 100 meshes and screened by a screen of 20 meshes. After being dried, the obtained particles are finished by adopting a 16 or 18-mesh sieve, so that the good fluidity of the particle powder is ensured. After finishing the granules, mixing with magnesium stearate, and tabletting.
Step three: tabletting
The weight of the tablet is 0.55 g/tablet, the environmental temperature is controlled to be 18-25 ℃, and the relative humidity is controlled to be 45-60%.
Step four: coating film
Coating uniform and compact film coat, controlling the ambient temperature at 18-25 ℃ and the relative humidity at 45-60%.
Step five: sterilization
Tabletting, forming and sterilizing.
Example 5
The method comprises the following steps: ingredients
900 parts of sea cucumber polypeptide, 100 parts of medlar polypeptide, 1000 parts of mulberry raw powder, 1000 parts of black sesame raw powder, 500 parts of nicotinamide mononucleotide, 500 parts of vitamin c, 25 parts of vitamin b, 65 parts of vitamin b 35 parts of vitamin b12 (1%), 1000 parts of microcrystalline cellulose, PVP K-3020 parts of PVP and 29 parts of magnesium stearate.
Step two: granulating
The nicotinamide mononucleotide is firstly and independently screened by a screen of 40 meshes or above and then fed (the raw material is easy to agglomerate and is unevenly dispersed), all components except magnesium stearate are fully mixed and screened by a screen of 40 meshes, and the nicotinamide mononucleotide is uniformly mixed with 200 parts by weight of 10-90% ethanol (dissolved with PVP-K30) of 100 meshes and screened by a screen of 20 meshes. After being dried, the obtained particles are finished by adopting a 16 or 18-mesh sieve, so that the good fluidity of the particle powder is ensured. After finishing the granules, mixing with magnesium stearate, and tabletting.
Step three: tabletting
The weight of the tablet is 0.55 g/tablet, the environmental temperature is controlled to be 18-25 ℃, and the relative humidity is controlled to be 45-60%.
Step four: coating film
Coating uniform and compact film coat, controlling the ambient temperature at 18-25 ℃ and the relative humidity at 45-60%.
Step five: sterilization
Tabletting, forming and sterilizing.
Example 6
The method comprises the following steps: ingredients
600 parts of sea cucumber polypeptide, 100 parts of wolfberry polypeptide, 700 parts of mulberry raw powder, 700 parts of black sesame raw powder, 1400 parts of nicotinamide mononucleotide, 500 parts of vitamin c, 25 parts of vitamin b, 65 parts of vitamin b 35 parts of vitamin b12 (1%), 1000 parts of microcrystalline cellulose, PVP K-3020 parts of PVP and 29 parts of magnesium stearate.
Step two: granulating
The nicotinamide mononucleotide is firstly and independently screened by a screen of 40 meshes or above and then fed (the raw material is easy to agglomerate and is unevenly dispersed), all components except magnesium stearate are fully mixed and screened by a screen of 40 meshes, and the nicotinamide mononucleotide is uniformly mixed with 200 parts by weight of 10-90% ethanol (dissolved with PVP-K30) of 100 meshes and screened by a screen of 20 meshes. After being dried, the obtained particles are finished by adopting a 16 or 18-mesh sieve, so that the good fluidity of the particle powder is ensured. After finishing the granules, mixing with magnesium stearate, and tabletting.
Step three: tabletting
The weight of the tablet is 0.55 g/tablet, the environmental temperature is controlled to be 18-25 ℃, and the relative humidity is controlled to be 45-60%.
Step four: coating film
Coating uniform and compact film coat, controlling the ambient temperature at 18-25 ℃ and the relative humidity at 45-60%.
Step five: sterilization
Tabletting, forming and sterilizing.
Example 7
The method comprises the following steps: ingredients
1000 parts of medlar polypeptide, 1000 parts of mulberry raw powder, 1000 parts of black sesame raw powder, 500 parts of nicotinamide mononucleotide, 450 parts of vitamin c, 50 parts of heme, 25 parts of vitamin b, 65 parts of vitamin b, 35 parts of vitamin b, 1.4 parts of vitamin b12 (1%), 1000 parts of microcrystalline cellulose, PVP K-3020 and 29 parts of magnesium stearate.
Step two: granulating
The nicotinamide mononucleotide is firstly and independently screened by a screen of 40 meshes or above and then fed (the raw material is easy to agglomerate and is unevenly dispersed), all components except magnesium stearate are fully mixed and screened by a screen of 40 meshes, and the nicotinamide mononucleotide is uniformly mixed with 200 parts by weight of 10-90% ethanol (dissolved with PVP-K30) of 100 meshes and screened by a screen of 20 meshes. After being dried, the obtained particles are finished by adopting a 16 or 18-mesh sieve, so that the good fluidity of the particle powder is ensured. After finishing the granules, mixing with magnesium stearate, and tabletting.
Step three: tabletting
The weight of the tablet is 0.55 g/tablet, the environmental temperature is controlled to be 18-25 ℃, and the relative humidity is controlled to be 45-60%.
Step four: coating film
Coating uniform and compact film coat, controlling the ambient temperature at 18-25 ℃ and the relative humidity at 45-60%.
Step five: sterilization
Tabletting, forming and sterilizing.
Example 8
The method comprises the following steps: ingredients
900 parts of sea cucumber polypeptide, 100 parts of medlar polypeptide, 1000 parts of mulberry raw powder, 1000 parts of black sesame raw powder, 500 parts of nicotinamide mononucleotide, 450 parts of vitamin c, 50 parts of heme iron, 25 parts of vitamin b, 65 parts of vitamin b 35 parts, 1.4 parts of vitamin b12 (1%), 1000 parts of microcrystalline cellulose, PVP K-3020 parts and 29 parts of magnesium stearate.
Step two: granulating
The nicotinamide mononucleotide is firstly and independently screened by a 40-mesh screen or more and then fed (the raw material is easy to agglomerate and is unevenly dispersed), all components except magnesium stearate are fully mixed and screened by a 40-mesh screen, and then the nicotinamide mononucleotide is uniformly mixed with 10-20mg of 10-90% ethanol (dissolved with PVP-K30) and screened by a 20-mesh screen. After being dried, the obtained particles are finished by adopting a 16 or 18-mesh sieve, so that the good fluidity of the particle powder is ensured. After finishing the granules, mixing with magnesium stearate, and tabletting.
Step three: tabletting
The weight of the tablet is 0.55 g/tablet, the environmental temperature is controlled to be 18-25 ℃, and the relative humidity is controlled to be 45-60%.
Step four: coating film
Coating uniform and compact film coat, controlling the ambient temperature at 18-25 ℃ and the relative humidity at 45-60%.
Step five: sterilization
Tabletting, forming and sterilizing.
Example 9
The method comprises the following steps: ingredients
500 parts of medlar polypeptide, 1000 parts of sea cucumber polypeptide, 1000 parts of mulberry raw powder, 1000 parts of black sesame raw powder, 450 parts of vitamin c, 50 parts of heme, 25 parts of vitamin b, 65 parts of vitamin b, 35 parts of vitamin b, 1.4 parts of vitamin b12 (1%), 1000 parts of microcrystalline cellulose, PVP K-3020 and 29 parts of magnesium stearate.
Step two: granulating
The nicotinamide mononucleotide is firstly and independently screened by a 40-mesh screen or more and then fed (the raw material is easy to agglomerate and is unevenly dispersed), all components except magnesium stearate are fully mixed and screened by a 40-mesh screen, and then the nicotinamide mononucleotide is uniformly mixed with 10-20mg of 10-90% ethanol (dissolved with PVP-K30) and screened by a 20-mesh screen. After being dried, the obtained particles are finished by adopting a 16 or 18-mesh sieve, so that the good fluidity of the particle powder is ensured. After finishing the granules, mixing with magnesium stearate, and tabletting.
Step three: tabletting
The weight of the tablet is 0.55 g/tablet, the environmental temperature is controlled to be 18-25 ℃, and the relative humidity is controlled to be 45-60%.
Step four: coating film
Coating uniform and compact film coat, controlling the ambient temperature at 18-25 ℃ and the relative humidity at 45-60%.
Step five: sterilization
Tabletting, forming and sterilizing.
Example 10
The method comprises the following steps: ingredients
1500 parts of wolfberry polypeptide, 1000 parts of mulberry raw powder, 1000 parts of black sesame raw powder, 450 parts of vitamin c, 50 parts of heme iron, 25 parts of vitamin b, 65 parts of vitamin b, 35 parts of vitamin b12 (1%), 1000 parts of microcrystalline cellulose, PVP K-3020 and 29 parts of magnesium stearate.
Step two: granulating
The nicotinamide mononucleotide is firstly and independently screened by a 40-mesh screen or more and then fed (the raw material is easy to agglomerate and is unevenly dispersed), all components except magnesium stearate are fully mixed and screened by a 40-mesh screen, and then the nicotinamide mononucleotide is uniformly mixed with 10-20mg of 10-90% ethanol (dissolved with PVP-K30) and screened by a 20-mesh screen. After being dried, the obtained particles are finished by adopting a 16 or 18-mesh sieve, so that the good fluidity of the particle powder is ensured. After finishing the granules, mixing with magnesium stearate, and tabletting.
Step three: tabletting
The weight of the tablet is 0.55 g/tablet, the environmental temperature is controlled to be 18-25 ℃, and the relative humidity is controlled to be 45-60%.
Step four: coating film
Coating uniform and compact film coat, controlling the ambient temperature at 18-25 ℃ and the relative humidity at 45-60%.
Step five: sterilization
Tabletting, forming and sterilizing.
Example 11
The method comprises the following steps: ingredients
1500 parts of wolfberry polypeptide, 1000 parts of mulberry raw powder, 1000 parts of black sesame raw powder, 500 parts of vitamin c, 25 parts of vitamin b, 65 parts of vitamin b, 35 parts of vitamin b, 1.4 parts of vitamin b12 (1%), 1000 parts of microcrystalline cellulose, PVP K-3020 and 29 parts of magnesium stearate.
Step two: granulating
The nicotinamide mononucleotide is firstly and independently screened by a 40-mesh screen or more and then fed (the raw material is easy to agglomerate and is unevenly dispersed), all components except magnesium stearate are fully mixed and screened by a 40-mesh screen, and then the nicotinamide mononucleotide is uniformly mixed with 10-20mg of 10-90% ethanol (dissolved with PVP-K30) and screened by a 20-mesh screen. After being dried, the obtained particles are finished by adopting a 16 or 18-mesh sieve, so that the good fluidity of the particle powder is ensured. After finishing the granules, mixing with magnesium stearate, and tabletting.
Step three: tabletting
The weight of the tablet is 0.55 g/tablet, the environmental temperature is controlled to be 18-25 ℃, and the relative humidity is controlled to be 45-60%.
Step four: coating film
Coating uniform and compact film coat, controlling the ambient temperature at 18-25 ℃ and the relative humidity at 45-60%.
Step five: sterilization
Tabletting, forming and sterilizing.
Example 12:
the raw materials are all food-grade and commercial products, and the black sesame raw powder (product number TGY-72033), the medlar polypeptide (product number TGY-4650), the mulberry raw powder (product number TGY4587), the sea cucumber extract (TGYSW25877) and the heme iron (product number TGY-461421) are all purchased from Guangyuan biological technology Limited company in Xian Tian; nicotinamide mononucleotide (cargo number aerial NMN) purchased from Shanghai aerial Biotech limited; vitamin B2, B3, B6, vitamin C, purity 99%, vitamin B12, effective content of 1%, all food grade, purchased from Yongyun Biotechnology Limited, Henan, nucleotide purchased from Yu food additives Limited, Kai, Zheng.
The production process of the raw powder comprises the following steps: cleaning raw materials, pretreating, extracting with water solution, filtering to obtain filtrate, concentrating, refining/purifying, drying, pulverizing, sieving, packaging to obtain the final product, and storing in storage.
Example 13
In the tabletting and granulating step, a wet granulating method is adopted, about 200 parts by weight of ethanol with the content of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90%, 95% and 100% are respectively adopted to mix and stir the components, and the viscosity and other states of the mixture after the ethanol with different contents is added are observed. Experimental observation shows that when the ethanol content is lower than 90%, the nicotinamide mononucleotide is extremely easy to agglomerate, has extremely high viscosity, cannot be dispersed and is sieved in the next step. The ethanol with the concentration higher than 90% can be used for well mixing and stirring the materials, and the dispersibility is increased along with the reduction of the water content. In the final granulation protocol, mixing and dispersion are preferably carried out with 100% ethanol.
Example 14
Temperature drying effect. In the wet granulation process, the sample mixed with ethanol is dried for a certain time at 40-60 ℃, and the drying is respectively carried out for 1 hour at 40 ℃, 2 hours at 40 ℃, 12 hours at 40 ℃, 1 hour at 60 ℃, 2 hours at 60 ℃ and 12 hours at 60 ℃, then the content of nicotinamide mononucleotide in the sample is measured by adopting high performance liquid chromatography, and through determination, the nicotinamide mononucleotide in the sample is not significantly degraded in the groups of 1 hour at 40 ℃ and 2 hours, the nicotinamide mononucleotide in the sample is degraded for about 3-5 percent in the groups of 1 hour at 60 ℃ and 2 hours at 60 ℃, the nicotinamide mononucleotide in the sample is degraded for 12 hours at 40 ℃, the degradation of the sample is 20 percent, the drying is carried out for 12 hours at 60 ℃, and the degradation of the sample is 30 percent. Through the experiment, in the granulation process, the sample after the ethanol mixing is dried preferably under the condition of drying at 40 ℃ for 1-2 hours, so that the inactivation and degradation of the nicotinamide mononucleotide are reduced to the maximum extent.
Example 15
The influence of the granularity of the black sesame raw powder on the hardness of the pressed tablet. The black sesame raw powder with different sources and processing modes has great influence on tablets after tabletting. The hardness of tablets obtained by tabletting with the mixture ratio of the examples 1 to 9 by using sesame powder which is directly crushed into powder and has the granularity of about 20 to 40 meshes is difficult to exceed 40. The original powder extracted according to the proportion of 10 to 1 after crushing is adopted, the granularity is about 80 to 100 meshes, and the hardness of the tablet obtained after tabletting according to the proportion of the examples 1 to 9 can exceed 40, so that the use requirement of the tablet is met.
Example 16
Performing cobalt 60 radiation sterilization treatment on the final tablet, performing sterilization treatment by respectively adopting two dose radiation intensities of 15 and 25kgry, and then performing content test on nicotinamide mononucleotide in the irradiated sample by adopting a high performance liquid chromatography. Tests show that the nicotinamide mononucleotide content of the sample is not obviously different after 15kgry irradiation. About 10-15% of the samples degraded after 25kgry irradiation. After the final preparation, on the premise of ensuring the activity of the nicotinamide mononucleotide, the radiation sterilization treatment is preferably carried out by adopting the intensity of 15 kgry.
While the present invention has been described with reference to the specific embodiments, the present invention is not limited thereto, and various changes may be made without departing from the spirit of the present invention.

Claims (24)

1. A composition containing multivitamins is characterized by comprising the following components in parts by weight:
vitamin b group, black sesame raw powder, mulberry raw powder and medlar polypeptide.
2. The composition of claim 1, wherein: the vitamin b group can be one or more of vitamin b2, b3, b6, b12, and vitamin b3 derivative Nicotinamide Mononucleotide (NMN).
3. Composition according to one of claims 1 to 2, characterized in that: the composition also comprises raw powder sea cucumber polypeptide and heme iron.
4. The composition according to one of claims 1 to 3, characterized in that: the composition also comprises vitamin c.
5. The composition according to any one of claims 1 to 4, characterized in that: the composition also comprises food additives of microcrystalline cellulose and pvp-k 30.
6. The composition according to any one of claims 1 to 5, characterized in that: the composition comprises the following components in parts by weight:
Figure FDA0003242971370000011
7. the composition of claim 6, wherein: the composition comprises the following components in parts by weight:
Figure FDA0003242971370000012
Figure FDA0003242971370000021
8. the composition of claim 7, wherein: the composition comprises the following components in parts by weight:
Figure FDA0003242971370000022
9. the composition of claim 8, wherein: the composition comprises the following components in parts by weight:
Figure FDA0003242971370000023
10. use of a composition according to any one of claims 1 to 9, characterized in that: the composition can be used for preparing health product or food with effects of improving alopecia, relieving fatigue, refreshing mind, and resisting aging.
11. A composition comprising a compound according to any one of claims 1 to 9, wherein the composition is a tablet.
12. The food or health product of claim 11, wherein: the content of Nicotinamide Mononucleotide (NMN) in the raw material composition is not less than 30-120 mg per tablet.
13. A process for the preparation of a food or health product according to claim 11 or 12, comprising the steps of:
(1) preparing materials;
(2) granulating;
(3) tabletting;
(4) coating;
(5) and (5) sterilizing.
14. The method of manufacturing according to claim 13, wherein: the ingredients in the step (1) comprise the following components in parts by weight:
Figure FDA0003242971370000031
15. the production method according to any one of claims 13 to 14, characterized in that: the granulation step in the step (2) is as follows: firstly, independently sieving Nicotinamide Mononucleotide (NMN) by a sieve of 40 meshes or more, then feeding, fully mixing all components except magnesium stearate, sieving by a sieve of 40 meshes, dissolving PVP-K30 with 100-200 parts by weight of 10-90% ethanol, uniformly mixing, and sieving by a sieve of 20 meshes; after being dried, the obtained particles are finished by adopting a 16 or 18-mesh sieve, so that the good flowability of the particle powder is ensured; after finishing the granules, mixing with magnesium stearate, and tabletting.
16. The production method according to any one of claims 13 to 15, characterized in that: the tabletting step in the step (3) is as follows: the weight of the tablet is 0.6 g/tablet, the environmental temperature is controlled to be 18-25 ℃, and the relative humidity is controlled to be 45-60%.
17. The production method according to any one of claims 13 to 16, wherein: the coating step in the step (4) is as follows: coating uniform and compact film coat, controlling the ambient temperature at 18-25 ℃ and the relative humidity at 45-60%.
18. The production method according to any one of claims 13 to 17, characterized in that: the sterilization step in the step (5) is as follows: tabletting, forming and sterilizing.
19. The production method according to any one of claims 13 to 18, wherein: in the preparation scheme of the tablet, the use ratio of the ethanol in the granulating step is 50-100%.
20. The method of claim 19, wherein: in the granulating step, the use ratio of the ethanol is 75-100%.
21. The method of claim 20, wherein: in the granulating step, the use ratio of the ethanol is 95-100%.
22. The production method according to any one of claims 13 to 21, wherein: in the granulating step, the granulating and drying temperature is 40-60 ℃, and the drying time is 1-12 hours.
23. The method of claim 22, wherein: in the granulating step, the granulating and drying temperature is 40 ℃, and the drying time is 1-2 hours.
24. The production method according to any one of claims 13 to 23, wherein: in the final sterilization step, cobalt 60 is selected for irradiation sterilization, the intensity is 15-25kgry, and 15kgry is selected to ensure that the active ingredients of the medicine are not damaged; the nicotinamide mononucleotide is prepared by adopting an enzymatic synthesis method, and the purity of the nicotinamide mononucleotide reaches more than 99%.
CN202111024930.7A 2021-09-02 2021-09-02 Composition containing compound vitamin and tabletting preparation method and application thereof Pending CN113826891A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111024930.7A CN113826891A (en) 2021-09-02 2021-09-02 Composition containing compound vitamin and tabletting preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111024930.7A CN113826891A (en) 2021-09-02 2021-09-02 Composition containing compound vitamin and tabletting preparation method and application thereof

Publications (1)

Publication Number Publication Date
CN113826891A true CN113826891A (en) 2021-12-24

Family

ID=78962047

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111024930.7A Pending CN113826891A (en) 2021-09-02 2021-09-02 Composition containing compound vitamin and tabletting preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN113826891A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115089553A (en) * 2022-06-21 2022-09-23 澳美制药(苏州)有限公司 Chewable tablet and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170266213A1 (en) * 2015-03-16 2017-09-21 Bontac Bio-Engineering (Shenzhen) Co., Ltd Use of beta-nicotinamide mononucleotide in preparation of anti-aging drugs or health-care products
CN109673751A (en) * 2019-01-29 2019-04-26 北京中科唯新生物医学研究所有限公司 A kind of preparation method and application of fruits and vegetables natural polypeptides combination composition chewable tablet
CN112674348A (en) * 2020-12-23 2021-04-20 石药集团中诺药业（泰州）有限公司 Preparation method of B-vitamin buccal tablet and chewable tablet

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170266213A1 (en) * 2015-03-16 2017-09-21 Bontac Bio-Engineering (Shenzhen) Co., Ltd Use of beta-nicotinamide mononucleotide in preparation of anti-aging drugs or health-care products
CN109673751A (en) * 2019-01-29 2019-04-26 北京中科唯新生物医学研究所有限公司 A kind of preparation method and application of fruits and vegetables natural polypeptides combination composition chewable tablet
CN112674348A (en) * 2020-12-23 2021-04-20 石药集团中诺药业（泰州）有限公司 Preparation method of B-vitamin buccal tablet and chewable tablet

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115089553A (en) * 2022-06-21 2022-09-23 澳美制药(苏州)有限公司 Chewable tablet and preparation method thereof

Similar Documents

Publication Publication Date Title
CN102224896B (en) Health food for enhancing human immunity and increasing bone mineral density and preparation method thereof
CN110338412A (en) The composition and its preparation of niacinamide-containing mononucleotide and ice plant and application
JP7332093B2 (en) Use of formulations based on mixtures of resveratrol with different pharmacokinetic profiles for improving female fertility.
WO2011047518A1 (en) Enteral nutrition comprising marine bioactive polysaccharide, preparation method and use thereof
CN104382892A (en) Composition for enhancing amount and activity of nitric oxide in human body and application thereof
CN109701027A (en) A kind of folic acid pharmaceutical composition and folic acid pharmaceutical preparation of novel enhancing folic acid antioxidant
CN113826891A (en) Composition containing compound vitamin and tabletting preparation method and application thereof
US20170209486A1 (en) Health-care preparation simultaneously with magnesium supplement and antioxidant functions and preparation method thereof
CN113170889A (en) Compound anti-aging composition, compound anti-aging tablet, and preparation method and application thereof
CN109381499A (en) A kind of horseradish composition and application thereof
CN114272273A (en) NMN-containing antioxidant composition and preparation method thereof
CN107712909A (en) A kind of iron zinc Muti-vitamine Oral Solution
CN105581331B (en) A kind of nutritional composition for calcium supplement
CN106213505A (en) A kind of Moringa Haematocoocus Pluvialls tabletting health product and preparation method thereof
CN101130065A (en) Soft capsule of pearl calcium and method of preparing the same
CN103655574A (en) Compound ferrous succinate and folic acid composition
CN104855863A (en) Chinese wolfberry functional food for improving body nitrogen monoxide content and preparing method thereof
KR20200107809A (en) Vitamin complex formula coated with xylitol and or Enzymatically Modified Stevia
CN111700870A (en) Production method of novel NMN + SFE compound medicament
KR101946164B1 (en) Breeding method of larva including organic germanium and organic selenium
KR102549896B1 (en) Capsule containing pyrroloquinolinequinone or a salt thereof and branched-chain amino acids
RU2436415C2 (en) Composition of biologically active substances based on betulin with regulated rate of releasing components for reducing degree of alcohol intoxication, preventing and relieving alcohol intoxication and alcohol withdrawal syndrome
CN114041549B (en) Preparation method of electrolyte effervescent powder and electrolyte effervescent powder
RU2323599C1 (en) Biologically active food additive and its production method
CN108294299A (en) A kind of spirulina powder and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211224